Roivant Sciences Ltd (NASDAQ:ROIV) said Tuesday that the U.S. Food and Drug Administration has accepted its New Drug Application for brepocitinib in dermatomyositis and granted the filing priority review status.
The application was submitted by Roivant’s subsidiary, Priovant. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date in the third quarter of 2026. Roivant said it is preparing for a potential commercial launch in September 2026, pending approval.
Priority review designation is reserved for therapies that could offer meaningful advances in safety or effectiveness for serious conditions. If approved, brepocitinib could provide a new treatment option for patients with dermatomyositis, a rare autoimmune disease characterized by muscle weakness and skin inflammation.
The accelerated review timeline shortens the FDA’s standard review period and signals that regulators view the therapy as having the potential to address a significant unmet medical need.